Switching From Semaglutide to Tirzepatide: What to Expect in 2026

Written by Nataliia Bondarchuk. Updated November 3, 2026.

Yes, you can switch from semaglutide to tirzepatide, but only with your prescriber, and there is no official one-to-one dose conversion. Semaglutide is the active ingredient in Ozempic and Wegovy; tirzepatide is the active ingredient in Mounjaro and Zepbound. Neither tirzepatide label gives switching instructions. Both labels start everyone at 2.5 mg once a week, and your prescriber decides whether you start there or higher. Any 'conversion chart' you find online is not based on the labels or on validated research. People usually switch because their weight loss has stalled, side effects, supply or cost. The best real-world data so far suggest switching helps most when weight loss has plateaued, and less when semaglutide never worked well. This guide covers how the two drugs differ, the head-to-head evidence, how a switch is usually done, what happens to the dose and side effects, and cost and insurance as of November 2026.

Both are once-weekly injections that reduce appetite and help control blood sugar. Semaglutide acts on one hormone receptor, GLP-1 (glucagon-like peptide-1), the gut hormone that signals fullness. Tirzepatide acts on GLP-1 and a second receptor, GIP (glucose-dependent insulinotropic polypeptide). That is why it is sometimes called a 'dual agonist'. Each ingredient is sold under two brand names: one for type 2 diabetes and one for weight management. The branded versions of each drug contain the same ingredient, as explained in Mounjaro vs Zepbound.

On average, yes, in the trials so far. SURMOUNT-5 randomized 751 adults with obesity but without diabetes to the highest tolerated dose of tirzepatide (10 or 15 mg) or semaglutide (1.7 or 2.4 mg) for 72 weeks. Weight fell by 20.2% with tirzepatide and 13.7% with semaglutide, and waist size fell by 18.4 cm against 13.0 cm.

In people with type 2 diabetes, SURPASS-2 compared three tirzepatide doses with semaglutide 1 mg in 1,879 adults over 40 weeks. All tirzepatide doses lowered A1C (a measure of average blood sugar) more than semaglutide, and weight loss was 7.8 to 12.4 kg against 6.2 kg. A large real-world analysis of 18,386 matched adults, published in JAMA Internal Medicine in 2024, found the gap grew over time: people on tirzepatide had lost 2.4 percentage points more at 3 months, 4.3 more at 6 months and 6.9 more at 12 months. Averages are not guarantees, and some people do very well on semaglutide. The full comparison is in tirzepatide vs semaglutide.

Yes. Neither the Mounjaro nor the Zepbound label covers switching, but clinicians do it routinely. Clinical guidance from the Obesity Medicine Association and the UK's Pharmaceutical Journal describes how. The key rule is to stop one before starting the other, not to take them together.

The most useful real-world study so far was published in the journal Obesity in 2026. Researchers at Weill Cornell looked back at 61 people who switched from semaglutide (at least 1.7 mg) to tirzepatide because their weight loss had stalled or they had not responded well. Over the next six months they lost an extra 5.3% of their body weight on average. The difference between groups was large. People who had plateaued after losing weight lost a further 8.1%. People who had never responded well lost 2.9%. This was a small study with no comparison group, so it cannot prove cause and effect. It does suggest that a plateau is a better reason to switch than a poor response from the start.

A smaller Lilly-funded study in people with type 2 diabetes, by Jabbour and colleagues (2024), moved participants on a stable GLP-1 drug, mostly semaglutide 1 mg, straight to tirzepatide 5 mg. According to a secondary summary of the study, after 12 weeks A1C had fallen a further 0.43% and weight a further 2.15 kg.

An expert consensus on switching between GLP-1 drugs (Jain and colleagues, 2021) lists the usual reasons: blood sugar not at target, wanting more weight loss, trouble sticking with treatment, side effects, cost, and changes to insurance or formulary (a plan's list of covered drugs). Not every stall means the drug has stopped working, so it is worth ruling out other causes first. Common ones are covered in why you may not be losing weight on tirzepatide.

There is no label-based protocol, so the details are your prescriber's call. The common approach looks like this:

If you miss your first tirzepatide dose, the Zepbound label says to take it within 4 days (96 hours); otherwise skip it and take the next one on schedule.

There is no official semaglutide to tirzepatide conversion. The Pharmaceutical Journal states there is 'no validated dose equivalence' between the two drugs. Both tirzepatide labels say to start at 2.5 mg once weekly for four weeks, then increase to 5 mg. After that, the dose can go up in 2.5 mg steps, at least four weeks apart. The Zepbound label says 2.5 mg 'is for treatment initiation and is not approved as a maintenance dosage'. Zepbound maintenance doses are 5, 10 or 15 mg for weight, or 10 or 15 mg for sleep apnea. The Mounjaro label says 2.5 mg 'is not intended for glycemic control' and allows increases up to 15 mg in adults.

Some prescribers start people coming off semaglutide at 5 mg instead. The Jabbour study tested a direct 5 mg start in type 2 diabetes. No US medical society has issued a formal recommendation either way, so the starting dose is your prescriber's decision. It depends on your current semaglutide dose, how well you tolerated it, and your health. We don't publish a conversion chart, because none is supported by the labels or by validated research. What each tirzepatide dose does is covered in tirzepatide dosage for weight loss, and what to expect in the first weeks is in how long it takes Zepbound to work.

They can. Tirzepatide causes the same kinds of digestive side effects as semaglutide: nausea, diarrhea, constipation and vomiting. These are most common when starting or raising the dose. Starting low is meant to reduce this. In the Jabbour switch study, about 13.2% of participants reported digestive side effects over 12 weeks, and 2% stopped because of side effects (figures from a secondary summary). We found no switch data on side-effect rates in people without diabetes.

For context, in SURMOUNT-5 fewer people stopped tirzepatide than semaglutide because of digestive side effects: 2.7% against 5.6%. Smaller meals, stopping before you feel full and limiting greasy food can help, as described in foods to eat on tirzepatide. How long symptoms usually last is in how long Mounjaro side effects last.

The process is similar, but the paperwork differs. Switching from Ozempic to Mounjaro is a diabetes-to-diabetes switch. The goal is usually blood sugar control, and coverage tends to follow diabetes rules. If you also take insulin or a sulfonylurea, your prescriber may lower those doses, because combining them with tirzepatide can cause low blood sugar. Switching from Wegovy to Zepbound is a weight-management switch, and weight-loss drugs are covered less often. Some plans only cover one brand, or ask you to try a preferred drug first (step therapy).

Self-pay prices, as reported in late 2025 and 2026 (check current prices before you decide):

The multi-dose pen is covered in the Zepbound KwikPen guide. With insurance, a switch is treated as a new prescription and usually needs a new prior authorization. The Obesity Medicine Association notes that plans may require step therapy. Coverage can change quickly. CVS Caremark, for example, dropped Zepbound from its standard formulary and made Wegovy its preferred weight-loss drug from July 1, 2025, moving existing prior authorizations to Wegovy. Formulary rules have kept changing since, and depend on your employer's plan. Before you stop semaglutide, confirm with your plan or pharmacy benefit manager that tirzepatide is covered for you as of November 2026.

Switching from semaglutide to tirzepatide is a reasonable option, especially if your weight loss has plateaued. Head-to-head trials show more weight loss on tirzepatide on average, and early real-world data show the most benefit in people who had plateaued. There is no official dose conversion. Both labels start at 2.5 mg, and your prescriber decides whether to start there or higher. Don't overlap the two drugs, expect some digestive side effects while the dose goes up, and check coverage before you stop your current prescription. If you later stop tirzepatide, weight tends to return, as explained in what happens when you stop tirzepatide.

This article summarizes drug labels and published research for general information and is not a substitute for medical advice. The Jabbour switch study was funded by Eli Lilly, which makes tirzepatide, and an author of the Pharmaceutical Journal guidance discloses a Lilly trainer role.